If that's the case why have there been zero insider buys? Actions speak louder than words. Would be a good question to ask if they hold Q&A at the analyst day. Stock price weakness as of late can be attributed to other antibacterial stocks getting hit e.g. $CBST, $OPTR
This is a very early stage biotech company any stock options that have been granted are not due to expire for years to come. You never see direct stock buys in early stage biotechs by management or directors as they all have stock options up the yingyang.
Insider buys in most cases for 90% of public companys when they do happen are just window dressing buys. IRMC.